No clear answer
Thioctic acid: reduce relapses and new lesions in secondary progressive MS
secondary progressive MS · Mitochondrial / oxidative stress
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 54
How the verdict was reached
No result yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Thioctic acid, phase 3 | Phase2|phase3 | 54 | 2010 | Other endpoint result After 2 years, the annualized PCBV was significantly less in the LA arm compared with placebo (-0.21 [standard error of the coefficient estimate (SEE) 0.14] vs -0.65 [SEE 0.10], 95% confidence interval [CI] 0.157-0.727, p = 0.002). Paper abstract | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026Status changed from Confirmed to No clear answer
- Oct 2026Status changed from Results pending to Confirmed
- Oct 2026Status changed from Confirmed to Results pending
- Oct 2026First listed as Confirmed
Related hypotheses
- Acetylcysteine: protect nerve tissue in secondary progressive MS
- Metformin: protect nerve tissue in secondary progressive MS
- Biotin: slow disability worsening in secondary progressive MS
- Metformin: slow disability worsening in secondary progressive MS
- Metformin: reduce relapses and new lesions in secondary progressive MS
Assembled by software from public sources.